Xinhua News Agency: Another innovative exploration! The research and evaluation base jointly established with Shanghai Customs and others is extraordinary

The "WTO/TBT-SPS National Notification and Consultation Center (Shanghai) Biomedical Technical Trade Measures Research and Evaluation Base" was recently unveiled in Shanghai, marking that China will more effectively respond to the challenges brought by international technical trade measures in the field of biomedicine in the future.
This base is jointly established by the International Inspection and Quarantine Standards and Technical Regulations Research Center of the General Administration of Customs, the Shanghai Science and Technology Commission, and Shanghai Customs. It is currently the only technical trade measure research and evaluation base for the biopharmaceutical industry in China.
According to the plan, this base will focus on international regulatory developments in cutting-edge fields such as antibody drugs, cell therapy, gene therapy, etc., and systematically carry out information collection, analysis and research, risk warning, and compliance response of technical trade measures, aiming to help Chinese enterprises more efficiently respond to the complex changes in the global drug regulatory environment.
Shanghai is a major hub of the national biopharmaceutical industry. Data shows that the scale of Shanghai's biopharmaceutical industry has increased from 761.714 billion yuan in 2021 to 984.702 billion yuan in 2024, with an average annual compound growth rate of 8.94%, and related innovative achievements continue to emerge. From 2021 to August 2025, a total of 30 domestically produced Class 1 innovative drugs were approved for market in Shanghai, accounting for 17% of the national total; In the field of cell and gene therapy, four products have been launched in Shanghai, accounting for 57% of the national market share.